PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 5, 20250 citations

Intravitreal Brolucizumab Shows Efficacy in Chronic Central Serous Chorioretinopathy

Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study.

View Full Paper

Authors

SCSomnath ChakrabortyJSJay ShethSGSantanu Ganguly

Discussion

Loading...

Member takes

Overview

Retrospective cohort study finds significant visual improvement in chronic central serous chorioretinopathy, indicating effectiveness of intravitreal brolucizumab.

Key Points

  • Vision improved significantly from baseline visual acuity of 0.59 logMAR to 0.39 logMAR at month 12.
  • Central retinal thickness reduced from 340 µm to 230 µm, indicating effective anatomical changes.
  • Resolved subretinal fluid was noted in 88.9% of eyes by month 12, highlighting treatment efficacy.
  • No ocular or systemic adverse events were reported, suggesting a favorable safety profile.
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chakraborty et al. (2025) studied this question.

synapsesocial.com/papers/68e2537cd6d66a53c24745b1https://doi.org/10.2147/opth.s550375
Ask AI
Helpful
Bookmark
Share
View Full Paper